Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Baxter
McKesson
Express Scripts
Dow

Last Updated: February 7, 2023

Ubrogepant - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for ubrogepant and what is the scope of patent protection?

Ubrogepant is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ubrogepant has ninety patent family members in forty-one countries.

One supplier is listed for this compound.

Summary for ubrogepant
International Patents:90
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 24
Clinical Trials: 11
Patent Applications: 146
What excipients (inactive ingredients) are in ubrogepant?ubrogepant excipients list
DailyMed Link:ubrogepant at DailyMed
Recent Clinical Trials for ubrogepant

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AbbViePhase 4
Chicago Headache Center & Research InstitutePhase 4
AllerganPhase 4

See all ubrogepant clinical trials

US Patents and Regulatory Information for ubrogepant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ubrogepant

Country Patent Number Title Estimated Expiration
Russian Federation 2019123406 ТЕХНОЛОГИЯ ПРИГОТОВЛЕНИЯ ТАБЛЕТОК ДЛЯ CGRP-АКТИВНЫХ СОЕДИНЕНИЙ See Plans and Pricing
Mexico 2016010169 FORMULACION DE TABLETA PARA COMPUESTOS ACTIVOS DE PEPTIDO RELACIONADO CON EL GEN DE CALCITONINA. (TABLET FORMULATION FOR CGRP-ACTIVE COMPOUNDS.) See Plans and Pricing
European Patent Office 2638042 DÉRIVÉS DE PIPÉRIDINONE CARBOXAMIDE AZAINDANE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR CGRP (PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS) See Plans and Pricing
Eurasian Patent Organization 022850 ПИПЕРИДИНОНКАРБОКСАМИДАЗАИНДАНЫ - АНТАГОНИСТЫ РЕЦЕПТОРА CGRP (PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2015119924 See Plans and Pricing
South Korea 20220136460 CGRP-활성 화합물에 대한 정제 제제 (CGRP- TABLET FORMULATION FOR CGRP-ACTIVE COMPOUNDS) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKesson
Johnson and Johnson
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.